Search clinical trials for: [18F]Florbetapir and PET imaging

Total 8458 results

Institute for Neurodegenerative Disorders
Biogen

Completed

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

Multiple Sclerosis

United States
Avid Radiopharmaceuticals

Completed

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Ruijin Hospital

Completed

Accurate Diagnosis of Multiple Sclerosis Using PET/MR

Multiple Sclerosis

China
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
University Hospital, Toulouse
Institut National de la Santé Et de la Recherche Médicale, France; Avid Radiopharmaceuticals

Completed

Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage (COGHIC-AV45)

Intracerebral Hemorrhage

France
Wuhan Union Hospital, China

Recruiting

The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis

PET/MR | Systemic Amyloidosis

China
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Progressive Cognitive Decline

United States
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Parkinson's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
Avid Radiopharmaceuticals

Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Reader Training Processes

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Healthy Volunteers

Alzheimer Disease

United States
Chang Gung Memorial Hospital

Unknown

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination (PMPBB3/AV45)

Alzheimer's Disease

Taiwan
Duke University

Withdrawn

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

Traumatic Brain Injury | Posttraumatic Stress Disorder | Alzheimer Dementia

United States
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
Mayo Clinic
Yale University; Columbia University; National Institute on Aging (NIA); Brigham... and other collaborators

Completed

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS) (KEEPS)

Alzheimer Dementia

United States
The Cleveland Clinic
Avid Radiopharmaceuticals

Terminated

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Cardiac Amyloidosis

United States
Brigham and Women's Hospital

Terminated

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Cardiac Amyloidosis

United States
Medical College of Wisconsin

Terminated

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

Cardiac Amyloidosis

United States
Eli Lilly and Company

Active, not recruiting

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD) (GERAS-US)

Alzheimer Disease | Mild Cognitive Impairment

United States
Avid Radiopharmaceuticals

Completed

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Alzheimer Disease

United States
Martin Dichgans
University Hospital Muenster; Universitätsklinikum Hamburg-Eppendorf

Recruiting

Inflammatory faCtors AfteR acUte Ischemic Stroke (ICARUS)

Ischemic Stroke

Germany
Columbia University

Active, not recruiting

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Metastatic Prostate Cancer

United States
Avid Radiopharmaceuticals

Completed

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Frontotemporal Dementia | Alzheimer's Disease

United Kingdom
Avid Radiopharmaceuticals
Eli Lilly and Company; PRA Health Sciences

Completed

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials (RAmP)

Alzheimer Disease | Cognition Disorders

United States
Avid Radiopharmaceuticals
General Electric; American College of Radiology Imaging Network

Completed

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Alzheimer's Disease

United States
Invicro

Completed

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

Alzheimer Disease | Healthy Volunteers | Progressive Supranuclear Palsy

United States
Mayo Clinic

Completed

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

Amyloidosis

United States
Invicro

Recruiting

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

Alzheimer Disease

United States
Molecular NeuroImaging
Roche Pharma AG; Institute for Neurodegenerative Disorders

Completed

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Alzheimer's Disease (AD)

United States
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation

Alzheimers Disease

United States
Avid Radiopharmaceuticals

Completed

Florbetapir Calibration to the Centiloid Scale

Alzheimer's Disease

United States, Australia
Avid Radiopharmaceuticals

Completed

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Alzheimer's Disease

United States
Lawson Health Research Institute
Canadian Institutes of Health Research (CIHR)

Completed

Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer (IGPC-3)

Prostate Cancer

Canada
Queen Mary University of London

Unknown

IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types (IMPACT)

Cancer

United Kingdom
University of Alabama at Birmingham

Recruiting

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

HER2-positive Breast Cancer

United States

Search clinical trials for: [18F]Florbetapir and PET imaging

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations